<DOC>
	<DOCNO>NCT02930837</DOCNO>
	<brief_summary>To evaluate safety efficacy alteplase administer 3 4.5 hour onset stroke symptom Chinese patient acute ischemic stroke</brief_summary>
	<brief_title>Safety Efficacy Alteplase When Administered Chinese Patients With Acute Ischemic Hemispheric Stroke Where Thrombolysis Initiated Between 3 4.5 Hours After Stroke Onset</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Inclusion criterion : Age &gt; = 18 year screen ( visit 1A ) &lt; = 80 year Signed dated write informed consent accordance good clinical practice local legislation prior admission trial Diagnosis ischemic stroke measureable neurological deficit National Institute Health Stroke Scale ( NIHSS ) Thrombolytic therapy initiate within 3 4.5 hour stroke onset Further inclusion criterion apply Exclusion criterion : Evidence intracranial haemorrhage ( ICH ) ( Computure Tomography ) CT/ ( Magnetic Resonance Imaging ) MRIscan symptom suggestive subarachnoid haemorrhage , even CT/MRIscan normal Acute bleeding diathesis Severe stroke assess clinically ( e.g . National Institute Health Stroke Scale &gt; 25 ) and/ image demonstrates multilobar infarction ( hypodensity &gt; 1/3 cerebral hemisphere ) Severe uncontrolled arterial hypertension , e.g . systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110mmHg , aggressive management ( intravenous medication ) necessary reduce blood pressure limit Blood glucose &lt; 50mg/ dL &gt; 400 mg/dL Any history prior stroke previous 3 month , history prior stroke concomitant diabetes Seizure stroke onset Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>